Articles related to DRUG EFFICACY

In a single-center randomized trial, mouth-dissolving clobazam and intranasal midazolam showed no statistically significant difference in clinical or electrographic seizure-termination time, supporting further study rather than establishing comparable efficacy.

The FDA has approved tavapadon, a selective D1/D5 dopamine receptor partial agonist, for adults with Parkinson disease following phase 3 studies demonstrating benefit both as monotherapy in early disease and as adjunctive therapy to levodopa.

A systematic review of 12 studies found that vortioxetine consistently improved depressive symptoms in adults aged 65 years and older with major depressive disorder, but evidence for cognitive benefits remained mixed and largely confined to selected cognitive domains.

In a large multinational target-trial emulation, adults with serious mental illness who initiated GLP-1 receptor agonists experienced lower mortality and cardiovascular event rates than matched patients initiating SGLT2 inhibitors, though residual confounding remains a key limitation.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.